establishment of of a a rational rational relationship between between

Similar documents
Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015

Clinically Relevant Specifications (CRS): A Regulatory Perspective

European Guidance on Modified Release Dosage Forms

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC

Guideline on quality of oral modified release products

In Vitro-In Vivo Correlation:

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Hydrostatic Bearings for Machine Tools

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

Guideline on quality of oral modified release products

Injectable modified release products

Application Strategy of PBPK for Generic Drugs and Its Current Challenges

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

Dissolution Apparatus Types

Dissolution and clinically relevant specifications: linking clinical performance to dissolution

Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives

Common Deficiences in Bioequivalence Studies and Biowaiver Requests submitted to the JFDA

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

BCS, Biowaivers and Dissolution Test Methodologies

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC

First UNGAP meeting Food-Drug Interactions Regulatory Aspects

Model based approaches to target special populations with rational formulation and clinical design strategies

Approach, Information needed and criteria- suggested by the members of the IQ dissolution WG

Who we are? Dissolution testing of modified release forms. Dissolution testing of immediate/ modified release forms

Kvantitativna analiza in R doc. dr. Franc Brcar

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

Draft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017

NUMERICAL OPTIMIZATION OF THE METHOD OF COOLING OF A MASSIVE CASTING OF DUCTILE CAST-IRON

Overview of comments received on 'guideline on quality of oral modified release products' (EMA/CHMP/QWP/428693/2013)

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE

Case Study: Merck & Co., Inc.

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

QbD and Applied Biopharmaceutics for Patient Benefit

Role of PBPK based virtual trials modeling in generic product development and regulation

IVIVC approach based on carbamazepine bioequivalence studies combination

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00.

USP s Perspective on Drug Product Performance Test

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS

Guidance for Industry

Cocrystals: A Regulatory Perspective. Scott L. Childs Renovo Research

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

Formulation Considerations for Over-Encapsulation of Clinical Trial Materials in DBcaps Capsules. Samantha Lai, Ph.D.

Dissolution Testing. Development / Quality Control and in vivo Relevance. 31 May 1 June 2017 Copenhagen, Denmark HIGHLIGHTS:

In vivo predictive biopharmaceutics tools for oral drug delivery

Eurofins ADME BIOANALYSES Your partner in drug development

BCS Guidance and Biowaivers BCS Monographs

Dissolution Testing Development / Quality Control and in vivo Relevance

QbD implementation in Generic Industry: Overview and Case-Study

Professor Andrea Laslop, MD, Austria

The role and future of dissolution testing in a QBD product development framework

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

US FDAs Perspective on Product Quality and Bioequivalence

In vitro - In vivo Correlation: From Theory to Applications

Regulatory Requirements of Dissolution for Generic Drug Products

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Public Assessment Report. Scientific discussion. Perindopril arginine Actavis (perindopril arginine) SE/H/1456/01-03/DC

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space

Line extension of immediate release products

In silico tools to study food-drug interactions, an Industry Perspective

Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats

INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT

The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible?

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets

How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products

Biowaivers: BCS and IVIVC

IN-VITRO AND IN-VIVO RELATIONSHIP AND INFLUENCE OF COVARIATES ON PHARMACOKINETICS OF URAPIDIL SUSTAINED RELEASE CAPSULES

Effect of Various Sustained Release Polymers on Naproxen Sodium Release from Control Release Tablets

Malleswari et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

The release of the drug substance from a solid dosage

SUPPLEMENTARY INFORMATION

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

The folowing four Rules-Of-Thumb summarize the more important aspects of electronic absorption:

Unit V APPLICATIONS OF PHARMACOKINETICS

Development of Quality Control Method for Dissolution Analysis of Tapentadol and paracetamolin tablet

Biopharmaceutics Applications in Drug Development

A Novel Comparative Evaluation for the Quality of Oral Generic Drugs

In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria

Comparative analysis of eight brands of sulfadoxinepyrimethamine

The development of novel dissolution approaches

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

Presentation Outline. Introduction Sources of Challenge for BE study

IMPROVING THE CORROSION RESISTANCE OF COMPONENTS MADE FROM STRUCTURAL STEELS

Carbon footprint. Špela Kern Umanotera, Slovenska fundacija za trajnostni razvoj E-pošta:

DEVELOPMENT OF ALUMINIUM ALLOYS FOR AEROSOL CANS

Varnost nanomaterialov: povezava med njihovimi lastnostmi in učinki na okolje

Stability studies of the optimized oral metoclopramide hydrochloride tablet formulations prepared for IVIVC studies

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

We embrace research and science, providing innovative products and integrated services to improve people s quality of life.

Regulatory Assessment

THERMOMECHANICAL PROCESSING OF MICRO-ALLOYED STEEL

SCIENTIFIC DISCUSSION

Dissolution Methodologies from Biorelevant to Quality Control The Challenges and Gaps

EFFECT OF TEMPERING ON THE ROOM-TEMPERATURE MECHANICAL PROPERTIES OF X20CrMoV121 AND P91 STEELS

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

MEDICINES CONTROL COUNCIL

Preclinical Development Discovery to IND

Transcription:

IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA Definicija po po USP: USP: The The term term in in vitro vitro -- in in vivo vivo correlation refers refers to to the the establishment of of a a rational rational relationship between between a a biological property, or or a a parameter derived derived from from a a biological property produced by by a a dosage dosage form, form, and and a a physicochemical property or or characteristic of of the the same same dosage dosage form. form. IN IN VITRO VITRO TESTI TESTI PO PO USP USP <701> <701> DISINTEGRATION <711> <711> DISSOLUTION APARATURE aparatura 1 aparatura 2 aparatura 3 aparatura 4 POSTOPKI immediate release release dosage dosage forms forms extended release release dosage dosage forms forms delayed delayed release release dosage dosage forms: forms: metodi metodi A in in B INTERPRETACIJA <724> <724> DRUG DRUG RELEASE Aparati, Aparati, predpisani v monografijah Transdermalni sistemi sistemi aparati aparati 5, 5, 6, 6, 7 1

2

USP31 3

USP31 USP31 4

...... USP31 <1088> <1088> IN IN VITRO VITRO AND AND IN IN VIVO VIVO EVALUATION OF OF DOSAGE FORMS IN IN VITRO VITRO (raztapljanje/sproščanje razvoj razvoj metod) metod) Oblike Oblike s s takojšnjim sproščanjem testiranje sproščanja zahtevano za za vse vse trdne trdne oblike, oblike, pri pri katerih katerih je je za za dosego dosego učinka učinka potrebna absorpcija. Izjeme! Izjeme! Oblike Oblike s s prirejenim sproščanjem testiranje sproščanja zahtevano za za vse vse sisteme, sisteme, pri pri katerih katerih je je za za dosego dosego učinka učinka potrebna absorpcija IN IN VIVO VIVO (SISTEMI S PRIREJENIM SPROŠČANJEM) karakterizacija učinkovine fizikalno kemijske lastnosti lastnosti farmakokinetične lastnosti lastnosti disposition properties farmakodinamične lastnosti lastnosti karakterizacija oblike oblike fizikalno kemijske lastnosti lastnosti farmakokinetične lastnosti lastnosti IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA oblike oblike s s prirejenim sproščanjem oblike oblike s s takojšnjim sproščanjem 5

NALOGA: V KATERIH OD OD NASLEDNJIH PRIMEROV LAHKO PRIČAKUJEMO DOBRO IN IN VITRO VITRO IN IN VIVO VIVO KORELACIJO? A) A) Učinkovina se se absorbira z z aktivnim transportom B) B) Učinkovina se se sprošča sprošča enakomerno 8 ur ur in in absorbira vzdolž vzdolžcelotnega jejunuma (ne (ne v želodcu, ne ne v ileumu ileumu in in kolonu) kolonu) C) C) Sproščanje poteka poteka z z enakomerno hitrostjo 10 10 mmol/h, absorpcija pa pa s s hitrostjo 2 2 mmol/h D) D) Sproščanje poteka poteka z z enakomerno hitrostjo 2 2 mmol/h, absorpcija pa pa s s hitrostjo 10 10 mmol/h IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA Definicija po po USP: USP: The The term term in in vitro vitro -- in in vivo vivo correlation refers refers to to the the establishment of of a a rational rational relationship between between a a biological property, or or a a parameter derived derived from from a a biological property produced by by a a dosage dosage form, form, and and a a physicochemical property or or characteristic of of the the same same dosage dosage form. form. 6

IN IN VITRO VITRO // IN IN VIVO VIVO KORELACIJA biološka lastnost: lastnost: farmakokinetičen parameter -- plazemski koncentracijski profili: profili: AUC, AUC, Cmax Cmax fizikalno kemijska lastnost: sproščanje učinkovine Nivoji Nivoji korelacije: nivo nivo A: A: najvišja najvišja stopnja stopnja korelacije point-to-point korelacija = celotni celotni profili profili nivo nivo B: B: primerjava parametrov (statističnih momentov): uporaba uporaba VSEH VSEH podatkov! MDT MDT // M(in M(in vivod)t nivo nivo C: C: primerjava v eni eni točki točki t50%, t50%, t90% t90% // AUC, AUC, tmax, tmax, Cmax Cmax Plazemski profil Profil sproščanja 7

Plazemski profil Absorpcijski profil Profil sproščanja Absorpcijski profil Profil sproščanja IVIVC 8